Journey Medical
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 58
- Market Cap
- $109.6M
- Introduction
Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.
Clinical Trials
10
Trial Phases
3 Phases
Drug Approvals
9
Drug Approvals
Minocycline Hydrochloride Foam
- Product Name
- 盐酸米诺环素泡沫剂
- Approval Number
- 国药准字HJ20240129
- Approval Date
- Nov 5, 2024
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks
- Conditions
- Rosacea
- Interventions
- Other: Placebo
- First Posted Date
- 2022-10-28
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT05597462
- Locations
- 🇺🇸
3A Research, LLC, El Paso, Texas, United States
A Comparative Bioavailability Study of DFD-29 Capsules 40 mg Versus SOLODYN® Tablets 105 mg, Under Fasting & Fed Conditions in Healthy Adult Human Subjects
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2022-07-11
- Last Posted Date
- 2023-03-02
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT05452785
- Locations
- 🇨🇦
CRO, Québec, Canada
A Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea (MVOR-2)
- Conditions
- Papulopustular Rosacea
- Interventions
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT05343455
- Locations
- 🇺🇸
Clinical Trial Site 15, Santa Monica, California, United States
🇺🇸Clinical Trial Site 01, Doral, Florida, United States
🇺🇸Clinical Trial Site 02, Miami, Florida, United States
A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.
- Conditions
- Papulopustular Rosacea
- Interventions
- First Posted Date
- 2022-03-25
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 323
- Registration Number
- NCT05296629
- Locations
- 🇺🇸
Clinical Trial Site 05, Rogers, Arkansas, United States
🇺🇸Clinical Trial Site 10, Cerritos, California, United States
🇺🇸Clinical Trial Site 03, Fremont, California, United States
A Study of Glycopyrronium Cloth, 2.4% in Patients With Palmar Hyperhidrosis
- Conditions
- Palmar Hyperhidrosis
- Interventions
- Drug: Vehicle
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- Journey Medical Corporation
- Target Recruit Count
- 72
- Registration Number
- NCT03880266
- Locations
- 🇺🇸
California Dermatology & Clinical Research Institute, Encinitas, California, United States
🇺🇸Colorado Medical Research Center, Inc., Denver, Colorado, United States
🇺🇸International Dermatology Research, Inc., Miami, Florida, United States
- Prev
- 1
- 2
- Next
News
Fortress Biotech Reports Strong 2024 Results with Two FDA Approvals and Strategic Acquisition Deal
Fortress Biotech secured FDA approvals for two key products in Q4 2024: Emrosi for inflammatory lesions of rosacea and UNLOXCYT for advanced cutaneous squamous cell carcinoma, with commercial launch of Emrosi already underway.
FDA Approves DermaSensor: First AI-Powered Skin Cancer Detection Device for Primary Care
DermaSensor has received FDA clearance for its handheld AI-powered device that detects skin cancer within seconds at point-of-care, achieving 96% sensitivity across all skin cancer types in clinical trials.
FDA Approves Emrosi (Minocycline Hydrochloride) for Rosacea Treatment in Adults
The FDA has approved Emrosi (minocycline hydrochloride) as a 40mg extended-release capsule for treating inflammatory lesions of rosacea in adults.
FDA Approves Journey Medical's Emrosi™ for Rosacea Treatment
The FDA has approved Emrosi™ (minocycline hydrochloride extended-release capsules, 40 mg) for treating inflammatory lesions of rosacea in adults.
Fortress Biotech's Emrosi Receives FDA Approval for Rosacea Treatment
The FDA approved Emrosi (minocycline hydrochloride extended-release capsules, 40mg) for treating inflammatory lesions of rosacea in adults, marking Fortress Biotech's first FDA approval.
Fortress Biotech Highlights FDA Approval of Emrosi and Cosibelimab's Upcoming PDUFA Date
Fortress Biotech announced FDA approval for Emrosi (minocycline hydrochloride) for treating inflammatory lesions of rosacea in adults, marking their first FDA approval.
Journey Medical's Emrosi Receives FDA Approval for Rosacea Treatment
Journey Medical's Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) has been approved by the FDA for treating inflammatory lesions of rosacea in adults.
FDA Approves Emrosi for Rosacea, Proposes Removal of Oral Phenylephrine
The FDA has approved Journey Medical's Emrosi (minocycline hydrochloride extended-release capsules) for treating inflammatory lesions of rosacea in adults, based on positive Phase 3 trial data.
FDA Approves Emrosi (Minocycline) for Rosacea Treatment
The FDA has approved Emrosi, an oral minocycline capsule, for treating rosacea in adults, offering a new option to manage the pimple-like bumps by reducing inflammation.
FDA Approves Journey Medical's Emrosi for Inflammatory Lesions of Rosacea
• The FDA has approved Journey Medical's Emrosi (minocycline hydrochloride) for treating inflammatory lesions of rosacea in adults. • Phase 3 trials demonstrated Emrosi's superiority over Oracea and placebo in Investigator's Global Assessment treatment success and lesion reduction. • Emrosi is expected to be available in late Q1 or early Q2 2025, with Journey Medical preparing for a successful launch. • Rosacea affects over 16 million people in the US, significantly impacting self-esteem and professional interactions.